BPI-371153
- Generic Name
- BPI-371153
A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma
- First Posted Date
- 2022-04-22
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 110
- Registration Number
- NCT05341557
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Chaoyang, Beijing, China
🇨🇳Cangzhou Central Hospital, Cangzhou, Hebei, China
🇨🇳Tianjin Cancer Hospital, Tianjin, Tianjin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath